MISSION
Mirum Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. We are passionate about advancing scientific discoveries to become important medicines for rare disease patients. We are collaborative, creative, and experienced professionals and we’re looking to augment our team with other individuals who embody our values: care, be real, get it done, and have fun, seriously.
The Regional Account Manager (RAM) is responsible for disease-state education and account-readiness activities in Hepatitis Delta Virus (HDV). This is a highly strategic, pre-launch role responsible for advancing disease awareness, supporting account readiness, and helping to establish the foundation for appropriate patient identification and management in a market with profound unmet need. The RAM will work across Infectious Disease, and community-based healthcare providers caring for patients with chronic Hepatitis B Virus (HBV) infection to improve awareness, screening, diagnosis, referral process, and education for HDV.
HDV represents the most severe form of viral hepatitis, requiring Hepatitis B co-infection for replication and spread. Despite an estimated U.S. prevalence of ~40,000 patients and ~15,000 who are diagnosed, insured, and under care, there are currently no approved therapies in the U.S., underscoring the urgency and importance of this role.
The successful candidate will thrive in ambiguity, demonstrate exceptional clinical credibility, and possess the entrepreneurial drive required to identify a market where established pathways and treatment paradigms do not yet exist.
Assigned Area: Los Angeles, Orange County, Inland Empire, San Diego
JOB FUNCTIONS/RESPONSIBILITIES
QUALIFICATIONS
Disease-State Market Development
Strategic Account Management
Thought Leader and Network Engagement
Cross-Functional Collaboration
Launch Readiness
QUALIFICATIONS AND REQUIREMENTS
#LI-REMOTE
Mirum Pharmaceuticals is committed to Equal Employment Opportunity (EEO) and to compliance with all Federal, State and Local laws that prohibit employment discrimination on the basis of race, age, national origin, ethnicity, religion, gender, gender identity, pregnancy, marital status, sexual orientation, citizenship, genetic disposition or characteristics, disability, veteran’s status or any other classification protected by applicable State/Federal/Local laws.
Mirum Pharmaceuticals provides reasonable accommodation for qualified individuals with disabilities and disabled veterans in job application procedures.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease. CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis (PBC). Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
